ES2332355T3 - Uso de cepas del virus parapox ovis contra fibrosis de organos. - Google Patents

Uso de cepas del virus parapox ovis contra fibrosis de organos. Download PDF

Info

Publication number: ES2332355T3
Authority: ES; Spain
Prior art keywords: fibrosis; parapox; cells; preparation; strains
Prior art date: 2000-07-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES01965110T

Other languages

English (en)

Spanish (es)

Inventor

Claudia Hirth-Dietrich

Tobias Schlapp

Angela Siegling

Andreas Knorr

Olaf Weber

Gudrun Theiss

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aicuris GmbH and Co KG

Original Assignee

Aicuris GmbH and Co KG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-11

Filing date

2001-07-11

Publication date

2010-02-03

2001-07-11 Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG

2010-02-03 Application granted granted Critical

2010-02-03 Publication of ES2332355T3 publication Critical patent/ES2332355T3/es

2021-07-11 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

206010016654 Fibrosis Diseases 0.000 title claims abstract description 20
230000004761 fibrosis Effects 0.000 title claims abstract description 17
241000283898 Ovis Species 0.000 title claims description 19
210000000056 organ Anatomy 0.000 title claims description 15
241000700605 Viruses Species 0.000 title description 15
241000700639 Parapoxvirus Species 0.000 claims abstract description 29
238000002360 preparation method Methods 0.000 claims abstract description 23
239000003814 drug Substances 0.000 claims abstract description 15
230000003449 preventive effect Effects 0.000 claims abstract description 13
210000004027 cell Anatomy 0.000 claims description 24
229940079593 drug Drugs 0.000 claims description 12
230000003510 anti-fibrotic effect Effects 0.000 claims description 11
230000009982 effect on human Effects 0.000 claims description 8
239000000825 pharmaceutical preparation Substances 0.000 claims description 7
230000006978 adaptation Effects 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 4
230000000374 effect on fibrosis Effects 0.000 claims description 4
238000011156 evaluation Methods 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
241000283690 Bos taurus Species 0.000 claims description 2
241001494479 Pecora Species 0.000 claims description 2
210000005260 human cell Anatomy 0.000 claims description 2
102000008186 Collagen Human genes 0.000 abstract description 13
108010035532 Collagen Proteins 0.000 abstract description 13
229920001436 collagen Polymers 0.000 abstract description 13
230000000694 effects Effects 0.000 abstract description 10
230000009466 transformation Effects 0.000 abstract description 8
201000010099 disease Diseases 0.000 abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
210000004024 hepatic stellate cell Anatomy 0.000 abstract description 2
230000002828 effect on organs or tissue Effects 0.000 abstract 1
241001465754 Metazoa Species 0.000 description 34
208000019425 cirrhosis of liver Diseases 0.000 description 24
210000002966 serum Anatomy 0.000 description 19
238000011282 treatment Methods 0.000 description 18
229950005499 carbon tetrachloride Drugs 0.000 description 16
210000004185 liver Anatomy 0.000 description 16
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 16
239000000243 solution Substances 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000002775 capsule Substances 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000002440 hepatic effect Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
239000006145 Eagle's minimal essential medium Substances 0.000 description 5
210000003995 blood forming stem cell Anatomy 0.000 description 5
230000007882 cirrhosis Effects 0.000 description 5
210000004051 gastric juice Anatomy 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
238000011534 incubation Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000011321 prophylaxis Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
102000007469 Actins Human genes 0.000 description 3
108010085238 Actins Proteins 0.000 description 3
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
108010082126 Alanine transaminase Proteins 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 3
102000016901 Glutamate dehydrogenase Human genes 0.000 description 3
238000008050 Total Bilirubin Reagent Methods 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000003902 lesion Effects 0.000 description 3
210000005228 liver tissue Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
235000015277 pork Nutrition 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 2
206010067125 Liver injury Diseases 0.000 description 2
108091027544 Subgenomic mRNA Proteins 0.000 description 2
229940087168 alpha tocopherol Drugs 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000008021 deposition Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000011389 fruit/vegetable juice Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000001524 infective effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
231100001143 noxa Toxicity 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000002245 particle Substances 0.000 description 2
231100000572 poisoning Toxicity 0.000 description 2
230000000607 poisoning effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
238000013223 sprague-dawley female rat Methods 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
239000002076 α-tocopherol Substances 0.000 description 2
235000004835 α-tocopherol Nutrition 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
241000700663 Avipoxvirus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
-1 GGT Proteins 0.000 description 1
108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000776474 Patescibacteria group Species 0.000 description 1
108010002885 Polygeline Proteins 0.000 description 1
235000018734 Sambucus australis Nutrition 0.000 description 1
244000180577 Sambucus australis Species 0.000 description 1
YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
231100000439 acute liver injury Toxicity 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000037319 collagen production Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000003352 fibrogenic effect Effects 0.000 description 1
208000036449 fibrotic liver disease Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
231100000753 hepatic injury Toxicity 0.000 description 1
210000000208 hepatic perisinusoidal cell Anatomy 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229960003350 isoniazid Drugs 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
210000000651 myofibroblast Anatomy 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229960004250 polygeline Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000000352 storage cell Anatomy 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000001629 suppression Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24261—Methods of inactivation or attenuation
- C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Addiction (AREA)
Biotechnology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Neurology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ES01965110T 2000-07-11 2001-07-11 Uso de cepas del virus parapox ovis contra fibrosis de organos. Expired - Lifetime ES2332355T3 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE10033581		2000-07-11
DE10033581		2000-07-11
DE10122233A DE10122233A1 (de)	2000-07-11	2001-05-08	Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
DE10122233		2001-05-08

Publications (1)

Publication Number	Publication Date
ES2332355T3 true ES2332355T3 (es)	2010-02-03

Family

ID=7648485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES01965110T Expired - Lifetime ES2332355T3 (es)	2000-07-11	2001-07-11	Uso de cepas del virus parapox ovis contra fibrosis de organos.

Country Status (14)

Country	Link
JP (2)	JP5587950B2 (de)
KR (1)	KR100845643B1 (de)
CN (1)	CN101444539B (de)
AT (1)	ATE445413T1 (de)
BR (1)	BRPI0112411B8 (de)
DE (2)	DE10122233A1 (de)
DK (1)	DK1303302T3 (de)
DO (1)	DOP2001000210A (de)
EC (1)	ECSP034420A (de)
ES (1)	ES2332355T3 (de)
PE (1)	PE20020218A1 (de)
PT (1)	PT1303302E (de)
SV (1)	SV2002000527A (de)
ZA (1)	ZA200300276B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102015111756A1 (de) *	2015-07-20	2017-01-26	Eberhard Karls Universität Tübingen Medizinische Fakultät	Rekombinanter Orf-Virus-Vektor
CA3018307A1 (en)	2016-02-16	2017-08-24	Osaka University	Pharmaceutical composition for use in treating fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4405841C1 (de) *	1994-02-23	1995-01-05	Mayr Anton Prof Dr Med Vet Dr	Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2125846T3 (es) *	1996-04-15	2001-12-16	Anton Prof Dr Med Vet Dr Mayr	Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.

2001
- 2001-05-08 DE DE10122233A patent/DE10122233A1/de not_active Withdrawn
- 2001-07-10 PE PE2001000681A patent/PE20020218A1/es not_active Application Discontinuation
- 2001-07-11 KR KR1020037000310A patent/KR100845643B1/ko not_active Expired - Fee Related
- 2001-07-11 ES ES01965110T patent/ES2332355T3/es not_active Expired - Lifetime
- 2001-07-11 DE DE50115181T patent/DE50115181D1/de not_active Expired - Lifetime
- 2001-07-11 PT PT01965110T patent/PT1303302E/pt unknown
- 2001-07-11 DK DK01965110.8T patent/DK1303302T3/da active
- 2001-07-11 AT AT01965110T patent/ATE445413T1/de active
- 2001-07-11 SV SV2001000527A patent/SV2002000527A/es not_active Application Discontinuation
- 2001-07-11 CN CN200810149856.XA patent/CN101444539B/zh not_active Expired - Lifetime
- 2001-07-11 BR BRPI0112411-0 patent/BRPI0112411B8/pt not_active IP Right Cessation
- 2001-07-11 DO DO2001000210A patent/DOP2001000210A/es unknown
2003
- 2003-01-10 ZA ZA200300276A patent/ZA200300276B/en unknown
- 2003-01-10 EC EC2003004420A patent/ECSP034420A/es unknown
2012
- 2012-06-28 JP JP2012145847A patent/JP5587950B2/ja not_active Expired - Lifetime
2014
- 2014-06-17 JP JP2014124405A patent/JP5950964B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE10122233A1 (de)	2002-01-24
BR0112411A (pt)	2003-05-27
BRPI0112411B8 (pt)	2021-05-25
CN101444539A (zh)	2009-06-03
DE50115181D1 (de)	2009-11-26
PE20020218A1 (es)	2002-05-19
JP2012214492A (ja)	2012-11-08
DOP2001000210A (es)	2002-12-15
ECSP034420A (es)	2003-03-10
ZA200300276B (en)	2004-04-13
CN101444539B (zh)	2016-07-06
JP2014196329A (ja)	2014-10-16
DK1303302T3 (da)	2010-02-08
PT1303302E (pt)	2009-11-11
KR20030019562A (ko)	2003-03-06
KR100845643B1 (ko)	2008-07-10
SV2002000527A (es)	2002-10-24
JP5587950B2 (ja)	2014-09-10
JP5950964B2 (ja)	2016-07-13
BRPI0112411B1 (pt)	2018-02-27
ATE445413T1 (de)	2009-10-15

Publication	Publication Date	Title
CN102858959B (zh)	2016-02-24	溶瘤弹状病毒
KR100279009B1 (ko)	2001-01-15	항바이러스제
ES2310580T3 (es)	2009-01-16	Composiciones purificadas del virus de la enfermedad de newcastle.
JP7399976B2 (ja)	2023-12-18	Ｃｏｖｉｄ－１９新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用
ES2332355T3 (es)	2010-02-03	Uso de cepas del virus parapox ovis contra fibrosis de organos.
CN113679716B (zh)	2024-03-26	溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
US6632647B2 (en)	2003-10-14	Use of strains of parapoxvirus ovis against organ fibrosis
CN117122693A (zh)	2023-11-28	经酸酐修饰的蛋白质抑制痘病毒的方法
ES2678053T3 (es)	2018-08-08	Inmunoestimulante que tiene una acción antineoplásica y procedimiento para producir dicho inmunoestimulante
US20230226136A1 (en)	2023-07-20	A synergistic formulation for management of respiratory pathogens including coronaviruses
ES2245248B1 (es)	2007-02-16	Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
EP4408448A1 (de)	2024-08-07	Pharmazeutische zusammensetzungen zur vorbeugung oder behandlung von virusinfektionen
CN105879058B (zh)	2017-11-14	一种结核病基因药物及其制备方法
RU2278683C1 (ru)	2006-06-27	Способ лечения респираторных заболеваний крупного рогатого скота
CN116139155A (zh)	2023-05-23	黎芦碱及黎芦提取物在制备抗病毒药物中的应用
WO2022005644A1 (en)	2022-01-06	Zinc porters, and their monoclonal antibody conjugates, for the prevention and treatment of covid-19 (sars-cov-2), other infections, and cancers
WO2022000167A1 (zh)	2022-01-06	转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
CN113827614A (zh)	2021-12-24	制备药用混合物的方法、所得药用混合物及其医药用途
CA2454167A1 (en)	2003-01-30	Use of a class of antiviral compounds to produce an agent for treating or preventing a virus infection in the respiratory tract
Kriek	0	IOUOnivIers~ ityIF~ ree~ St~ ate~~~~~~~~~ 34300002088221 Universiteit Vrystaat The Oncolytic Properties of Two Newcastle Disease Virus Strains.
Girigosavi	0	Hantavirus: Past and Future
HK1060050A (en)	2004-07-30	Use of strains of the parapox ovis virus against organ fibrosis